Cover Kidney News
Volume/Issue:
Volume 13: Issue 7
Page:
29
Publication Date:
01 Jul 2021
Online Publication Date:
07 Jul 2021
Figure 1.

Treatments for primary hyperoxaluria type 1 (PH1)
  • 1.

    Garrelfs SF, et al. Lumasiran, an RNAi therapeutic for primary hyperoxaluria type 1. N Engl J Med 2021; 384:1216–1226. doi: 10.1056/NEJMoa2021712

Lumasiran Offers a New, Effective Treatment for Primary Hyperoxaluria Type 1 (PH1)

Stephanie Perez Kerkvliet Stephanie Perez Kerkvliet, MD, is a Pediatrics Resident Physician, and Michelle N. Rheault, MD, is Director, Division of Pediatric Nephrology, and Associate Professor of Pediatrics, University of Minnesota Masonic Children's Hospital, in Minneapolis.

Search for other papers by Stephanie Perez Kerkvliet in
Current site
Google Scholar
PubMed Close
and
Michelle N. Rheault Stephanie Perez Kerkvliet, MD, is a Pediatrics Resident Physician, and Michelle N. Rheault, MD, is Director, Division of Pediatric Nephrology, and Associate Professor of Pediatrics, University of Minnesota Masonic Children's Hospital, in Minneapolis.

Search for other papers by Michelle N. Rheault in
Current site
Google Scholar
PubMed Close
Volume/Issue:
Volume 13: Issue 7
Publication Date:
01 Jul 2021
Page:
29
Restricted access
Save